FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study

A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

NCT04767529 ·Status: COMPLETED ·Phase: PHASE2

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

NCT06528314 ·Status: RECRUITING ·Phase: PHASE3

A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis

NCT06903065 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Investigate Safety, Tolerability, PK/PK of J2H 1702 in Healthy Males

NCT06308861 ·Status: COMPLETED ·Phase: PHASE1

The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)

NCT01265498 ·Status: COMPLETED ·Phase: PHASE2

Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)

NCT00740610 ·Status: COMPLETED ·Phase: PHASE2

Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)

NCT02854605 ·Status: COMPLETED ·Phase: PHASE2

Investigate Safety, Tolerability, PK/PD of J2H-1702 in Healthy Females

NCT06308874 ·Status: COMPLETED ·Phase: PHASE1

2-Week Study In People With Nonalcoholic Fatty Liver Disease

NCT03513588 ·Status: COMPLETED ·Phase: PHASE1

A Study to Understand How the Study Medicine (PF-07081532) is Processed in People With Liver Dysfunction

NCT05478603 ·Status: COMPLETED ·Phase: PHASE1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus

NCT01899703 ·Status: COMPLETED ·Phase: PHASE2

Phase 2b Study of GSK4532990 in Adults With NASH

NCT05583344 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal Hepatic Function

NCT02452801 ·Status: COMPLETED ·Phase: PHASE1

A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease

NCT02927314 ·Status: COMPLETED ·Phase: PHASE2

The Impact of Everolimus Based Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver Transplantation

NCT01707849 ·Status: COMPLETED ·Phase: PHASE3

A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of HEC96719 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis

NCT05397379 ·Status: COMPLETED ·Phase: PHASE2

Phase 2a Study to Evaluate Safety and Explore Efficacy of J2H-1702 for NASH

NCT06297434 ·Status: COMPLETED ·Phase: PHASE2

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

NCT06215716 ·Status: RECRUITING ·Phase: PHASE3

Clinical Trial to Investigate the Anti-oxidant Activity of Heptex in Patients With Apparent Risk Factors of NASH

NCT05343780 ·Status: COMPLETED ·Phase: PHASE2

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis

NCT03486912 ·Status: COMPLETED ·Phase: PHASE2

Safety and Tolerability of HepaStem in Patients With Cirrhotic and Pre-cirrhotic NASH Patients

NCT03963921 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Phase 2a Study of HPG1860 in Subjects With NASH

NCT05338034 ·Status: UNKNOWN ·Phase: PHASE2

A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH

NCT02279524 ·Status: COMPLETED ·Phase: PHASE2

Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis

NCT03439254 ·Status: COMPLETED ·Phase: PHASE3

Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis

NCT04048876 ·Status: TERMINATED ·Phase: PHASE2